India  

Serum Institute of India

Indian biotechnology and biopharmaceuticals company

Serum Institute of India    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Serum Institute of India: Indian biotechnology and biopharmaceuticals company


0
shares
ShareTweetSavePostSend
 

You Might Like


Age is just a number, look at Ratan Tata, Bachchan: NCP Lok Sabha member Supriya Sule takes on Ajit Pawar

"Some people are saying that people who are senior now should give us their blessings (and retire). Why should they stop working? Ratan Tata who heads India's largest conglomerate is 86 years old...
IndiaTimes - Published

Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory: Bombay HC

The Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and..
IndiaTimes - Published

'Elderly people can...': SII's CEO Adar Poonawalla's big remark on Covid spike in India

India has recorded 12,193 fresh Covid-19 cases in 24 hours. The number of active cases climbed to 67,556.
DNA - Published

Covovax for adults to reach metros in a week: SII

Serum Institute of India’s CEO Adar Poonawalla told TOI on Friday that doses of Covovax — Covid booster shot for adults — would reach major cities in four to five days, while a Bharat Biotech..
IndiaTimes - Published

SII to restart vaccine production amid surge in Covid cases

Serum Institute of India CEO Adar Poonawalla told TOI on Wednesday that the company has resumed production of its Covid-19 vaccine, Covishield, in response to the increasing number of SARS-CoV-2 virus..
IndiaTimes - Published

Serum Institute of India restarts manufacturing of Covid-19 vaccine Covishield

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the..
IndiaTimes - Published

Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adults


IndiaTimes - Published

India well-prepared to combat any future waves: SII CEO Adar Poonawalla amid Covid scare in China


IndiaTimes - Published

Drug panel favours nod for Covovax as Covid booster

An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have..
IndiaTimes - Published

Covovax may get approval as heterologous booster

The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for..
IndiaTimes - Published

Covovax vaccine to get booster dose approval in 10-15 days: SII CEO Adar Poonawalla


IndiaTimes - Published

Covid situation in India better than elsewhere: SII CEO Adar Poonawalla

Serum Institute CEO Adar Poonawalla on Sunday lauded India's fight against the Covid pandemic, saying the government and the healthcare workers contributed largely to tackling the pandemic. "Everyone..
IndiaTimes - Published

Serum Institute to provide 2 crore Covishield doses to central govt free of cost


IndiaTimes - Published

News of rising covid cases coming out of China is concerning: Adar Poonawalla

Covid has made a comeback in China and the world is worried about its spread. Adar Poonawalla of the SII has spoken about it.
DNA - Published

HPV vaccine production delayed due to Covid focus, will start supply to Indian govt in early 2023: SII

Serum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023,..
IndiaTimes - Published

SII's Adar Poonawalla makes clarion call for global certification of vaccines

"Multilateral organisations such as the United Nations and the World Trade Organisation should take it upon themselves to harmonise the certification of vaccines," Adar Poonawalla told PTI on the..
IndiaTimes - Published

Scammers send fake message in CEO Adar Poonawalla's name, dupe Serum Institute of Rs 1 crore

Fraudsters allegedly attempted to con one of SII's directors by sending him a WhatsApp message asking him to wire money to numerous other accounts.
DNA - Published

Fraudsters dupe Serum Institute of Rs 1 cr by asking for money transfer in CEO's name


IndiaTimes - Published

Bombay HC issues notice to Central govt, Bill Gates, Serum Institute over plea on alleged Covid vaccine death


IndiaTimes - Published

Cost of cervical cancer vaccine set to be Rs 200-400

Cervavac, India's first indigenously developed vaccine for preventing cervical cancer caused by Human Papilloma Virus (HPV), is likely to be priced between Rs 200-400 per dose, Serum Institute of India..
IndiaTimes - Published

SII will try to launch Omicron-specific vaccine after six months: Adar Poonawalla


IndiaTimes - Published Also reported by •DNA

Desi qHPV vaccine against cervical cancer to be launched today

India is all set to launch on Thursday its first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for prevention of cervical cancer. It has been developed by the Serum Institute..
IndiaTimes - Published

Vaccine for Omicron likely in 6 months: SII’s Poonawala

The vaccine will be specific to the BA5 sub-variant of the Omicron strain, SII CEO Adar Poonawalla told a TV channel, adding that he thought “this vaccine is important as a booster”.
IndiaTimes - Published

SII CEO meets Mandaviya to discuss research on possible monkeypox vax


IndiaTimes - Published

Serum Institute of India to launch indigenously made vaccine to treat cervical cancer

Serum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenously-developed vaccine to treat cervical cancer in women later this year.
IndiaTimes - Published

SII gets govt nod to export 32.4 lakh doses of Covovax vaccine to US

The government has allowed Serum Institute of India (SII) to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported..
IndiaTimes - Published

Covid-19 vaccine: SII's Covovax gets nod for emergency use in children aged 7 to 11 years

The DCGI had approved Covovax for restricted emergency use in adults on December 28, 2021, and in 12-17 years age group on March 9, 2022.
DNA - Published

Govt panel recommends emergency approval for SII's Covovax for 7-11 year olds

An expert panel of India's central drug authority on Friday recommended granting emergency use authorisation to Serum Institute's Covovax for children aged 7 to 11 years, official sources said. The..
IndiaTimes - Published

Covid-19 vaccine: SII significantly lowers price of each dose of Covovax

This comes a day after Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres.
DNA - Published

Covid-19 vaccine Covovax now available for children in India: Adar Poonawalla

Serum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the Covid-19 vaccine Covovax is now available in India for children. He also hailed PM Narendra Modi for his vision of providing..
IndiaTimes - Published

Govt unlikely to procure SII’s Covovax for 12-17 age group

As majority of youngsters has already taken the first dose of Covid vaccine, the government is unlikely to procure Serum Institute of India’s Covovax for use in adolescents of 12-17 years under the..
IndiaTimes - Published

NTAGI panel recommends inclusion of Covovax in inoculation drive for 12-17 age group

Serum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, r
DNA - Published

Covid-19: Serum Institute of India halts vaccine production over millions of unused doses

Serum Institute of India Ltd., the world’s largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its..
IndiaTimes - Published

Reduce time gap for Covid vaccine booster dose to six months: Serum Institute to govt

Vaccine major Serum Institute of India (SII) has appealed to the government to reduce the gap between the second and booster dose to six months from nine months at present to safeguard people against..
IndiaTimes - Published

Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot


IndiaTimes - Published

Covishield, Covaxin prices slashed ahead of booster drive expansion

Serum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..
IndiaTimes - Published

Serum Institute of India prices Covishield booster dose at Rs 600

SII CEO Adar Poonawalla also welcomed the government's move to allow precautionary doses of the vaccine to all aged above 18 years.
DNA - Published

Serum Institute's Covishield precaution dose priced at Rs 600 per shot

Vaccine maker Serum Institute of India (SII) on Friday said the precaution dose of its Covishield vaccine against Covid-19 will be priced at Rs 600 per shot for eligible individuals.
IndiaTimes - Published

SII’s Covovax for those aged 12+ gets panel nod

The Covid-19 working group under the government’s vaccine advisory body has recommended use of the Serum Institute of India’s Covovax in the national vaccination programme for those aged 12 years..
IndiaTimes - Published

Novavax says its Covid vaccine gets India authorisation for adolescents

Novavax Inc on Tuesday said that the Drugs Controller General of India (DCGI) has granted emergency use authorisation for its Covid-19 vaccine for adolescents aged 12 to 17 in the country. The..
IndiaTimes - Published

Covid-19: Covovax gets DCGI’s EUA nod for 12-17-year-olds

In a move that will further expand the basket of Covid vaccines approved for adolescents, the drug regulator has given emergency approval to Serum Institute of India’s Covovax for use in 12-17 year..
IndiaTimes - Published

DCGI's EUA nod to Covovax for 12-17 years age group

India's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official..
IndiaTimes - Published

Covid-19: SII's Covovax vaccine recommended for Phase 3 trial as booster dose in adults

The Pune-based SII had sought the permission from the DCGI to conduct Phase 3 study to evaluate the safety and immunogenicity of Covovax.
DNA - Published

Government panel recommends EUA for Covid vaccine Covovax for 12-17 age group

Prakash Kumar Singh, director-government and regulatory affairs at Serum Institute of India (SII), had submitted an application to the DCGI on February 21, seeking EUA for Covovax for the 12 to 17..
IndiaTimes - Published

SII seeks permission for Covovax vaccine phase-3 study of booster dose in adults

The Drugs Controller General Of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on December 28.
DNA - Published

230 kids aged 2-6 become youngest to get Covid jabs in Covovax trial

A group of 230 children aged two to six have become the youngest in the country to get a Covid vaccine after they were given at least one dose during trials of the Covovax jab, manufacturer Serum..
IndiaTimes - Published

SII makes available vaccines at price of 'cup of tea' to poor nations, says Cyrus Poonawalla


IndiaTimes - Published

Serum Institute has applied for full market authorisation of Covishield: CEO Adar Poonawala

Serum Institute has applied to the Indian health ministry and Central Drugs Standard Control Organisation (CDSCO) for full market authorisation for its Covishield vaccine, company's CEO Adar Poonawalla..
IndiaTimes - Published

Bio E's Corbevax, SII's Covovax & antiviral drug Molnupiravir get EUA nod

In a significant boost for India’s fight against Covid-19, the Central Drugs Standard Control Organisation (CDSCO) has granted emergency use authorisation for two more Covid-19 vaccines – Corbevax..
IndiaTimes - Published

No robust trial data, government rejects SII and Bio E’s proposals on booster jabs


IndiaTimes - Published


 Page 1  âŚŞ